行情

CHRS

CHRS

Coherus生物科技
NASDAQ

实时行情|Nasdaq Last Sale

22.50
0.00
0.00%
盘后: 22.50 0 0.00% 16:06 02/20 EST
开盘
22.41
昨收
22.50
最高
23.03
最低
22.01
成交量
121.48万
成交额
--
52周最高
23.91
52周最低
12.95
市值
15.78亿
市盈率(TTM)
-117.1265
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CHRS 新闻

  • 欧盟公布新数字战略对抗美科技巨头
  • 新浪财经综合.3小时前
  • 《消费者报告》首次将特斯拉Model 3列为"首选车型"
  • 新浪美股.4小时前
  • Coherus BioSciences Announces New Employment Inducement Grants
  • GlobeNewswire.5小时前
  • 低利率的大背景下 市政债券或成“新贵”
  • 新浪财经-自媒体综合.5小时前

更多

所属板块

生物技术和医学研究
-0.11%
制药与医学研究
-0.42%

热门股票

名称
价格
涨跌幅

CHRS 简况

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
展开

Webull提供Coherus Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。